A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401

Lung Cancer

Volumn 74, Issue 1, 2011, Pages 80-84

  Nogami, Naoyuki ^a   Hotta, Katsuyuki ^b   Kuyama, Shoichi ^c   Kiura, Katsuyuki ^b   Takigawa, Nagio ^b   Chikamori, Kenichi ^d   Shibayama, Takuo ^e   Kishino, Daizo ^d   Hosokawa, Shinobu ^f   Tamaoki, Akihiko ^g   Harita, Shingo ^c   Tabata, Masahiro ^b   Ueoka, Hiroshi ^d   Shinkai, Tetsu ^a   Tanimoto, Mitsune ^b  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c CHUGOKU CENTRAL HOSPITAL   (Japan)

^d NATIONAL SANYO HOSPITAL   (Japan)

^e Department of Internal Medicine   (Japan)

^f Okayama Red Cross Hospital   (Japan)

^g Okayama Institute of Health and Prevention   (Japan)

Author keywords

Amrubicin; Chemo naive; Lung cancer; Refractory relapse; Sensitive relapse; Topotecan

Indexed keywords

AMRUBICIN; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; GRANISETRON; GYRASE INHIBITOR; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; ILEUS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; VOMITING;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; RECURRENCE; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; TOPOTECAN; TREATMENT OUTCOME;

EID: 80052577998     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.018     Document Type: Article

References (19)

1. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85-91.
2. Hanna N., Bunn P.A., Langer C., Einhorn L., Guthrie T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24:2038-2043.
3. Krug L.M., Kris M.G., Rosenzweig K., Travis W.D. Small cell lung cancer. Cancer: principles and practice of oncology 2008, 946-971. Lippincott-Raven, Philadelphia. 8th 302 ed. V.T. De 301 Vita, S. Hellman, S.A. Rosenberg (Eds.).
4. Oze I., Hotta K., Kiura K., Ochi N., Takigawa N., Fujiwara Y., et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 2009, 4:e7835.
5. Ettinger D.S. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol 2001, 28:27-29.
6. Yana T., Negoro S., Takada Y., Yokota S., Fukuoka M. Phase II study of amrubicin (SM-5887), a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC): a West Japan Lung Cancer Group Trial. Proc Am Soc Clin Oncol 1998, 17:450c. The West Japan Lung Cancer Group, [abstr 1734].
7. Schiller J.H., Kim K., Hutson P., DeVore R., Glick J., Stewart J., et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996, 14:2345-2352.
8. Shibayama T., Hotta K., Takigawa N., Tada A., Ueoka H., Harita S., et al. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Lung Cancer 2006, 53:189-195.
9. Stahel R., Aisner J., Ginsberg R., et al. Staging and prognostic factors in small cell lung cancer. Lung Cancer 1989, 5:119.
10. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
11. Hotta K., Fujiwara Y., Kiura K., Tabata M., Takigawa N., Ueoka H., et al. Relationship between response rate and survival in over 50,000 patients of advanced non-small-cell lung cancer treated with systemic chemotherapy. J Thorac Oncol 2007, 2:402-407.
12. Heigener D.F., Freitag L., Eschbach C., Huber R.M., Fink T., Hummler S., et al. Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): final results of a randomised phase III trial. J Clin Oncol 2008, 26. [May 20 suppl.; abstr 7513].
13. Ohe Y., Negoro S., Matsui K., Nakagawa K., Sugiura T., Takada Y., et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 2005, 16:430-436.
14. Inoue A., Sugawara S., Yamazaki K., Maemondo M., Suzuki T., Gomi K., et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008, 26:5401-5406.
15. Ettinger D.S., Jotte R., Lorigan P., Gupta V., Garbo L., Alemany C., et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010, 28:2598-2603.
16. Okamoto I., Hamada A., Matsunaga Y., Sasaki J., Fujii S., Uramoto H., et al. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother Pharmacol 2006, 57:282-288.
17. Onoda S., Masuda N., Seto T., et al. Phase II trial of amrubicin for treatment of tefractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006, 24:5448-5453.
18. Souhami R.L., Spiro S.G., Rudd R.M., Ruiz de Elvira M.C., James L.E., Gower N.H., et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997, 89:577-580.
19. Girling D.J. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial Medical Research Council Lung Cancer Working Party. Lancet 1996, 348:563-566.